IL17A and metabolic dysfunction-associated steatotic liver disease: Empagliflozin significantly enhances the autophagy of liver macrophages through the AMPK/mTOR signaling pathway, inhibits the expression level of IL-17/IL-23 axis-related molecules, reduces inflammatory response, and improves NAFLD-related liver injury.